MarketCap
Facebook
X
TelegramQuarterly report 2024-Q1
added 05-09-2024
Alpine Immune Sciences Operating Cash Flow 2011-2025 | ALPN
Annual Operating Cash Flow Alpine Immune Sciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -43.8 M | -15.2 M | 30.1 M | -35.3 M | -28.4 M | -16.6 M | -3.8 M | 4.82 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.1 M | -43.8 M | -13.5 M |
Quarterly Operating Cash Flow Alpine Immune Sciences
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.7 M | - | - | - | -26.2 M | - | -27 M | -10.6 M | 5.45 M | - | -519 K | -30.7 M | -16 M | - | 39.4 M | 44.8 M | -9.69 M | - | -29.7 M | -19.1 M | -11.2 M | - | -19 M | -11.6 M | -4.43 M | - | -10.7 M | -6.05 M | -2.16 M | - | -2.03 M | -13.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 44.8 M | -30.7 M | -8.55 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptevo Therapeutics
APVO
|
-23.8 M | $ 0.56 | -7.02 % | $ 155 K |  USA |
 |
Aclaris Therapeutics
ACRS
|
-20.1 M | $ 3.03 | - | $ 234 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.2 | 2.56 % | $ 7.7 B |  Australia |
 |
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.89 | 12.87 % | $ 482 M |  Britain |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 1.14 | - | $ 6.22 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-15.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 209.97 | 0.47 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
BioVie
BIVI
|
-19 M | $ 1.17 | -3.31 % | $ 1.73 M | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-25.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 0.18 | -15.83 % | $ 392 M |  Israel |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 94.82 | 0.31 % | $ 27.2 B | Germany |
 |
Catalyst Biosciences
CBIO
|
25.9 M | $ 12.23 | -1.01 % | $ 805 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
213 M | $ 26.84 | -1.03 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
-66.3 M | - | -10.95 % | $ 876 K | USA |
 |
Anika Therapeutics
ANIK
|
-1.79 M | $ 9.5 | -0.52 % | $ 139 M | USA |
 |
Certara
CERT
|
80.5 M | $ 8.87 | -0.28 % | $ 1.42 B | USA |
 |
bluebird bio
BLUE
|
-235 M | - | - | $ 546 M | USA |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 4.91 | 3.47 % | $ 116 M | France |
 |
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Axon Enterprise
AXON
|
408 M | $ 580.5 | -0.57 % | $ 44 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.53 | 3.27 % | $ 15.9 M | USA |
 |
AstraZeneca PLC
AZN
|
5.96 B | $ 92.54 | -0.39 % | $ 96.9 B | Britain |
 |
ChromaDex Corporation
CDXC
|
12.1 M | - | -0.88 % | $ 598 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 9.21 | 1.32 % | $ 1.49 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 26.0 | -1.53 % | $ 1.67 M | USA |